An interventional study of Nasopharyngeal swab sampling for COVID-19 in COVID-19 and Inflammatory Response, sponsored by Hadassah Medical Organization. Recruiting at 6 sites in Israel. Open to participants aged 0 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-03-14.
Sponsored by Hadassah Medical Organization · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in COVID-19 with a site in Israel — 4 open to participants now, 7 under way, 3 of them phase 3. COVID-19 · Israel.
Among the 91 studies in COVID-19 with a site in Israel, this one is the 12th largest by planned enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2024, is one of 19 with no phase, and was the 89th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →4 of the 91 studies in COVID-19 with a site in Israel are open now. Recruiting first, the newest first:
Assaf-Harofeh Medical Center · Sites in Israel
Ages 18+
AstraZeneca · Sites in Israel, United States, Argentina and 36 more countries
Ages 18+
UMC Utrecht · Sites in Israel, United States, Australia and 26 more countries
Ages 28 days+
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 0 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 27 · Phase 3 14 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 56 across the 61 interventional studies, 300 across the 29 observational. Of the 51 that completed or were terminated, 10 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 91 have an industry lead sponsor. The 10 most frequent:
Hadassah Medical Organization is the lead sponsor of 675 studies on the registry; 54 are open to participants now.
Hadassah Medical Organization has 6 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies in COVID-19 with a site in Israel that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add it to your calendar (.ics) → With an account.
Among the 91 studies in COVID-19 with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Even though the COVID-19 pandemic is no longer at its peak, the threat still lingers. Engaging in prospective surveillance studies will enable us to monitor the disease and prepare for any potential resurgence. COVID-19 surveillance studies are essential tools for policymakers to make informed decisions, allocate resources, and develop strategies to control the spread of the virus and protect public health.
The objective of this surveillance study is to prospectively assess in-hospital severe morbidity related to COVID-19 infection in children who present to the Pediatric Emergency Department (ED).
A prospective multicenter study will be conducted across eight EDs in Israel and five EDs in the United Kingdom. The study population will include children aged 16 years or younger with a severe acute COVID-19 infection. Confirmation of acute COVID-19 infection will be based on polymerase chain reaction nasopharyngeal swab testing. The study will also include patients diagnosed with multisystem inflammatory syndrome in children (MIS-C), as defined by the CDC.
Inclusion Criteria:
SACI
Patients aged 16 years or younger with a positive COVID-19 PCR nasopharyngeal swab testing or bronchoalveolar sample who meet the definition of SACI:
Nasopharyngeal swab sampling for COVID-19
Diagnostic Test: Nasopharyngeal swab sampling for COVID-19
The healthcare provider will gently insert the swab a short distance (1-1.5 cm for young children) into one nostril, reaching the back of the nasal cavity. The swab will then be gently rotated and rubbed for a few seconds to collect a sample of mucus. The same process may be repeated in the other nostril.
Severe acute COVID-19 infection (SACI)
The percentage of patients diagnosed with SACI among all patients admitted to the Emergency Department
Time frame: Up to 16 weeks
Administration of low-flow oxygen therapy via nasal cannula or face mask
The percentage of COVID-19 patients treated with low-flow oxygen among all patients admitted to the Emergency Department
Time frame: Up to 12 weeks
Administration of high-flow oxygen via nasal cannula (HFNC), or administration of oxygen via bilevel or continuous positive airway pressure (CPAP) machine
The percentage of COVID-19 patients treated with HFNC or CPAP among all patients admitted to the Emergency Department
Time frame: Up to 12 weeks
Treatment with mechanical ventilation
The percentage of COVID-19 patients treated with mechanical ventilation among all patients admitted to the Emergency Department
Time frame: Up to 12 weeks
Treatment with extracorporeal membrane oxygenation (ECMO)
The percentage of COVID-19 patients treated with ECMO among all patients admitted to the Emergency Department
Time frame: Up to 8 weeks
Treatment with vasopressor support
The percentage of COVID-19 patients treated with vasopressor support among all patients admitted to the Emergency Department
Time frame: Up to 8 weeks
Length of ICU stay
Mean duration of ICU stay for patients admitted with COVID-19
Time frame: Up to 16 weeks
Length of hospital stay
Mean duration of hospital stay for patients admitted with COVID-19
Time frame: Up to 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Aug 2026, 23 months after the start.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 23 months is above that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hadassah Medical Organization →